Indeed, IDH1 mutations have an adverse prognostic effect in AML and constitute a drug‐targetable gene alteration.19, 20SRSF2 mutations are classically associated with poor outcome.21, 22WT1 mutations are defined as a secondary event in AML and the unknown nonsense variant described here could have a pejorative impact.23 This evidence concerns the gene IDH1 and acute myeloid leukemia.